New vaccine trial aims to better protect vulnerable blood cancer patients from COVID-19
NCT ID NCT04977024
Summary
This study is testing whether a new COVID-19 vaccine called GEO-CM04S1 can trigger a stronger immune response than the standard mRNA vaccines in a particularly vulnerable group. It involves 63 adults with blood cancers (like leukemia or lymphoma) who have received a stem cell transplant or other cellular therapy. Researchers will compare the safety and immune system reactions to the two vaccines to see if the new option offers better protection against COVID-19 for these high-risk patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, 27157, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
SUNY-Stony Brook
Stony Brook, New York, 11794, United States
-
U Mass Chan Medical School
Worcester, Massachusetts, 01655, United States
Conditions
Explore the condition pages connected to this study.